Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development [Yahoo! Finance]
LivaNova PLC - Ordinary Shares (LIVN)
Last livanova plc - ordinary shares earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
livanova.com
Company Research
Source: Yahoo! Finance
Strengthens Xeltis' leadership team following IDE approval for initiation of US pivotal study for aXess ™ , its restorative vascular access conduit EINDHOVEN, The Netherlands Nov. 5, 2024 /PRNewswire/ -- Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has appointed Luc Verhees as its new Vice President of Clinical Business Development. Luc's appointment further strengthens the Company's leadership team, as Xeltis expands its clinical presence following the approval of an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a US pivotal study for aXess, its restorative vascular access conduit. Luc is familiar to Xeltis having previously served as Senior Vice President of Global Clinical Affairs from 2018 to 2020, and this previous experience of working with Xeltis' transformative Endogenous Tissue Restoration (ETR) technology in a clinical capa
Show less
Read more
Impact Snapshot
Event Time:
LIVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIVN alerts
High impacting LivaNova PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
LIVN
News
- LivaNova PLC (NASDAQ: LIVN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- How stimulating the body's largest nerve may relieve severe depression [CNN]CNN
- For those with treatment-resistant depression, vagus nerve stimulation may be an answer, studies suggest [CNN]CNN
- RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression [Yahoo! Finance]Yahoo! Finance
- RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant DepressionBusiness Wire
LIVN
Earnings
- 10/30/24 - Beat
LIVN
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- LIVN's page on the SEC website